Activation of the kinase AXL induces EGFR-TKI resistance associated with the mesenchymal phenotype [87,88], and the dual blockade of MEK and AXL overcomes EMT-mediated drug resistance and synergistically suppresses tumor growth in KRAS-mutated lung cancer cells [91]. The gene discussed is EGFR; the disease is neoplasm.